Publication
Legal strategies to tackle fraud in early-stage investments in Asia
In the wake of the recent eFishery scandal early-stage investors are recalibrating their approach to due diligence and risk tolerance.
Global | Publication | March 2017
NHS England has published new guidelines on managing conflicts of interest. The guidance will come into force on 1 June 2017. It will be applicable to Clinical Commissioning Groups, NHS Trusts and NHS Foundation Trusts, and NHS England.
The guidance covers common situations which can give rise to risk of conflicts of interest including gifts, hospitality and providing expertise outside employment, by:
Organisations should require staff to comply with the guidance and to proactively declare interests. An organisation will consider a range of actions from deciding no action is warranted to removing an individual from their role altogether if the conflict is so significant that they are unable to operate effectively in it.
The NHS England guidance has been aligned with The Association of the British Pharmaceutical Industry (ABPI) Code of Practice, particularly as it relates to the principles and rules for gifts and hospitality. Organisations are also required to seek to ensure that staff are subject to wider transparency initiatives such as the ABPI’s Disclosure UK.
Disclosure UK, launched in June 2016, is a searchable database detailing transfers of values made to healthcare professionals and healthcare organisations by pharmaceutical companies. The database is the means by which UK pharmaceutical companies comply with their transparency obligations under the ABPI Code of Practice.
Publication
In the wake of the recent eFishery scandal early-stage investors are recalibrating their approach to due diligence and risk tolerance.
Publication
As we stand on the cusp of transformative change within the energy sector, anticipation builds around the UK government’s impending decision on the Review of Electricity Market Arrangements (REMA). This briefing provides a recap of the proposals made to date and looks at the potential future impact of the REMA proposals on market players.
Publication
Antitrust authorities are increasingly aggressive in pursuing new theories of harm, pushing the boundaries of what amounts to an antitrust violation, and expanding the use of current legislation and regulation to fit a new era of issues.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025